Email
RSS27/11/08 - 04:22 ... source : Wyeth
... and Tarrytown, N.Y., November 26, 2008 – Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that a phase 3 clinical study investigating RELISTOR® (methylnaltrexone bromide) subcutaneous injection ...
25/11/08 - 08:15 ... source : American Society for Therapeutic Radiology and Oncology - ASTRO
24/11/08 - 11:23 ... source : Genentech
... PFS Benefit With Capecitabine, As Well As With Anthracycline-Based Chemotherapies -- South San Francisco, Calif. -- November 23, 2008 -- Genentech, Inc. (NYSE:DNA) today announced that a Phase III study (RIBBON 1) of Avastin® (bevacizumab), ...
22/11/08 - 05:28 ... source : Amgen
... and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin ...
20/11/08 - 17:39 ... source : Roche
... today announced that the SATURN (SequentiAl Tarceva in UnResectable NSCLC) study met its primary endpoint of progression free survival. The study showed that Tarceva (erlotinib), when given in first line maintenance - immediately following initial ...
20/11/08 - 17:20 ... source : Watson Pharmaceuticals
... WPI), a leading specialty pharmaceutical company, today announced that its New Drug Application (NDA) for a 6-month formulation of TRELSTAR(R) (triptorelin pamoate), a luteinizing hormone releasing hormone (LHRH) agonist, has been accepted for filing by ...
20/11/08 - 16:49 ... source : Johnson & Johnson
20/11/08 - 12:44 ... source : GlaxoSmithKline
... the Netherlands Vaccine Institute (NVI) as the cervical cancer vaccine for the Dutch National Immunisation Programme (NIP). Issued: Thursday 20th November 2008, London UK GlaxoSmithKline's (GSK) cervical cancer vaccine, Cervarix TM, was today confirmed by ...
19/11/08 - 13:34 ... source : AstraZeneca
... ZACTIMA (vandetanib) in combination with chemotherapy agents docetaxel (ZODIAC) and pemetrexed (ZEAL) and as monotherapy (ZEST) in non-small cell lung cancer (NSCLC). Results from the ZODIAC and ZEAL studies showed advantages for vandetanib in combination ...
19/11/08 - 06:07 ... source : Sanger Institute
... Directions Publications Press Releases 2008 Latest Release Nov 18 Nov 06 Oct 31 Oct 30 Oct 08 Sep 17 Sep 11 Jul 27 Jul 16 Jul 02 Jun 11 Jun 08 May 16 May 15 ...
